BioReact

Based in the US, BioReact delivers advanced bioprocess optimization solutions utilizing AI technology to enhance data management for bioprocess scientists, enabling them to streamline their workflows and improve efficiency. BioReact, founded in 2023 and headquartered in Indianapolis, US, specializes in AI-driven solutions for bioprocess optimization. The founder has not been disclosed, nor are there known subsidiaries or parent companies associated with BioReact. BioReact Software is a leading provider of AI-powered bioprocess optimization solutions aimed at revolutionizing the way bioprocess scientists manage and analyze their data.

Their core product utilizes proprietary algorithms to convert siloed bioprocess data into actionable insights, thereby streamlining the optimization of bioreactor parameters. By leveraging advanced statistical analyses such as PCA, ANOVA, and Factor Importance, the software facilitates the automatic alignment of both online and offline time-series data, enabling scientists to predict ideal growth conditions, nutrient requirements, and environmental factors crucial for enhancing process performance. BioReact primarily serves biotechnological firms, research institutions, and laboratories in the United States, Europe, and Asia, where there is a growing need for efficient data management and optimization solutions in bioprocess research and development. The revenue model for BioReact relies on a subscription-based framework, where clients, including bioprocess scientists and researchers, engage with the software through annual subscriptions or project-based licenses.

This transaction structure allows for consistent revenue generation as clients continually utilize the platform for ongoing optimization efforts in their bioprocesses. The flagship offerings include the BioReact software, which is tailored to provide in-depth data analysis and visualization, enhancing productivity and ultimately leading to significant cost savings for clients. Specific pricing plans are designed to cater to various organizational needs, ensuring that both large research firms and smaller laboratories can benefit from the advanced functionalities of BioReact’s solutions. Through strategic partnerships and direct sales efforts, the company maintains a robust client base within the biotechnology sector.

In December 2025, BioReact raised USD 1. 07 million in pre-seed round led by New Stack Ventures with participation from FortySix Venture Capital, Plug and Play, Service Provider Capital and Hurricane Ventures. The company will utilize this funding to expand its bioprocess data platform and accelerate the development and release of new features. BioReact is focused on expanding into new geographic regions, particularly targeting additional markets in Europe and Asia by 2027.